Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2019

Nov 14, 2019

SELL
$39.36 - $76.8 $787,200 - $1.54 Million
-20,000 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$52.76 - $82.19 $1.06 Million - $1.64 Million
20,000 New
20,000 $1.56 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Ratan Capital Management LP Portfolio

Follow Ratan Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ratan Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Ratan Capital Management LP with notifications on news.